中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2013年
47期
14-15
,共2页
各种晚期恶性肿瘤%吉西他滨顺铂%紫杉醇%卡培他滨%以吉西他滨为主化疗方案
各種晚期噁性腫瘤%吉西他濱順鉑%紫杉醇%卡培他濱%以吉西他濱為主化療方案
각충만기악성종류%길서타빈순박%자삼순%잡배타빈%이길서타빈위주화료방안
Advanced cancer%Gemcitabine%Cisplatin%Paclitaxel%Capecitabine%Gemcitabine-based chemotherapy regimens
目的:观察吉西他滨为主化疗方案治疗各种晚期恶性肿瘤的临床疗效观察及副反应观察。方法60例各种晚期癌症患者,经病理学,影响学,实验室检测确诊。其中初治19例,曾经多程化疗患者41例。应用吉西他滨+顺铂,吉西他滨+紫杉醇,吉西他滨+卡培他滨。二药联合方案。据患者不同病情及既往化疗方案以及ECOG状况选择不同以上二药联合方案。均能化疗2-4周期或4-6周期化疗,评价疗效。结果总有效率(CR+PR)53.3%,其中CR3例, P R29例,S D18例,P D10例。主要毒副反应骨随抑制3-4度为中性粒细胞减少占60%,血小板抑制3-4度占48%。恶心呕吐1-2度。结论吉西他滨为主化疗方案治疗各种晚期恶性肿瘤疗效较好,毒副反应能耐受,值得临床应用。
目的:觀察吉西他濱為主化療方案治療各種晚期噁性腫瘤的臨床療效觀察及副反應觀察。方法60例各種晚期癌癥患者,經病理學,影響學,實驗室檢測確診。其中初治19例,曾經多程化療患者41例。應用吉西他濱+順鉑,吉西他濱+紫杉醇,吉西他濱+卡培他濱。二藥聯閤方案。據患者不同病情及既往化療方案以及ECOG狀況選擇不同以上二藥聯閤方案。均能化療2-4週期或4-6週期化療,評價療效。結果總有效率(CR+PR)53.3%,其中CR3例, P R29例,S D18例,P D10例。主要毒副反應骨隨抑製3-4度為中性粒細胞減少佔60%,血小闆抑製3-4度佔48%。噁心嘔吐1-2度。結論吉西他濱為主化療方案治療各種晚期噁性腫瘤療效較好,毒副反應能耐受,值得臨床應用。
목적:관찰길서타빈위주화료방안치료각충만기악성종류적림상료효관찰급부반응관찰。방법60례각충만기암증환자,경병이학,영향학,실험실검측학진。기중초치19례,증경다정화료환자41례。응용길서타빈+순박,길서타빈+자삼순,길서타빈+잡배타빈。이약연합방안。거환자불동병정급기왕화료방안이급ECOG상황선택불동이상이약연합방안。균능화료2-4주기혹4-6주기화료,평개료효。결과총유효솔(CR+PR)53.3%,기중CR3례, P R29례,S D18례,P D10례。주요독부반응골수억제3-4도위중성립세포감소점60%,혈소판억제3-4도점48%。악심구토1-2도。결론길서타빈위주화료방안치료각충만기악성종류료효교호,독부반응능내수,치득림상응용。
To observe the efficacy and side effects of gemcitabine-based chemotherapy regimens for al sorts of patients with advanced cancer. Methods:60 cases of patients with advanced cancer who had been dignosed through pathology, imaging and laboratory tests, received the gemcitabine-based chemotherapy regimens (gemcitabine+ Cisplatin or paclitaxel or capecitabine). 20 cases were newly diagnosed, 40 cases had received repeated chemotherapy. According to the patient's condition to select a different program. Evaluated after 2-4 or 4-6 cycles. Results:The totle response rate(CR+PR)was 53.3 %,(3 cases CR,29 cases PR,18 cases SD,10 cases PD). The main side effects was myelosuppression. Those with grade 3-4 neutropenia accounted for 60%, with grade 3-4 hrombocytopenia accounted for 48%.A secondary reaction was grade 1-2 Nausea and vomiting. Conclusion: These results indicate that the gemcitabine-based chemotherapy regimens is a safe and effective regimen for patients with advanced cancer,and the toxicity can be tolerated.